This article is a correction to:
Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases
Elias Zgheib1*
Alice Limonciel2
Xiaoqi Jiang3
Anja Wilmes2
Steven Wink4
Bob van de Water4Annette Kopp-Schneider3
Frederic Y. Bois5*
Paul Jennings2- 1Laboratoire de Biomécanique et Bio-ingénierie, Sorbonne Universités – Université de Technologie de Compiègne, Compiègne, France
- 2Division of Molecular and Computational Toxicology, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
- 3Division of Biostatistics, German Cancer Research Center, Heidelberg, Germany
- 4Division of Drug Discovery and Safety, Leiden Cell Observatory High Content Imaging Screening Facility, Leiden Academic Center for Drug Research, Leiden University, Leiden, Netherlands
- 5Models for Ecotoxicology and Toxicology Unit (DRC/VIVA/METO), Institut National de l'Environnement Industriel et des Risques, Verneuil-en-Halatte, France
A Corrigendum on
Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases
by Zgheib, E., Limonciel, A., Jiang, X., Wilmes, A., Wink, S., van de Water, B., et al. (2018). Front. Genet. 9:429. doi: 10.3389/fgene.2018.00429
In the original article, we neglected to mention that this work was partly supported by the EU-ToxRisk project (An Integrated European “Flagship” Program Driving Mechanism-Based Toxicity Testing and Risk Assessment for the 21st Century) funded by the European Commission under the Horizon 2020 programme (Grant Agreement No. 681002).
A correction has therefore been made to the Acknowledgments:
“The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking (IMIJU) under grant agreement number 115439, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. This work was supported by the 2015 CEFIC-LRI award (AL) and partly supported by the EU-ToxRisk project (An Integrated European “Flagship” Program Driving Mechanism-Based Toxicity Testing and Risk Assessment for the 21st Century) funded by the European Commission under the Horizon 2020 programme (Grant Agreement No. 681002). This publication reflects only the author's views and neither the IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: transcriptomics, Nrf2, AhR, ATF4, toxicity pathways, toxicogenomic, oxidative stress
Citation: Zgheib E, Limonciel A, Jiang X, Wilmes A, Wink S, van de Water B, Kopp-Schneider A, Bois FY and Jennings P (2019) Corrigendum: Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases. Front. Genet. 10:517. doi: 10.3389/fgene.2019.00517
Received: 11 May 2019; Accepted: 13 May 2019;
Published: 04 June 2019.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2019 Zgheib, Limonciel, Jiang, Wilmes, Wink, van de Water, Kopp-Schneider, Bois and Jennings. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frederic Y. Bois, frederic.bois@certara.com; Elias Zgheib, elias.zgheib.pro@gmail.com